-
Mashup Score: 2Phase 1/2 Study of Ixazomib with Cyclophosphamide and Dexamethasone (IxaCyD) in Newly Diagnosed AL Amyloidosis - PubMed - 2 year(s) ago
Phase 1/2 Study of Ixazomib with Cyclophosphamide and Dexamethasone (IxaCyD) in Newly Diagnosed AL Amyloidosis
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1The Stem Cell Transplant Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Stem Cell Transplant Daily! https://t.co/OLcdMjAUSO Thanks to @Myeloma_Doc @VincentRK #myeloma #ninlaro
-
-
Mashup Score: 0Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis - PubMed - 2 year(s) ago
Bortezomib, a proteasome inhibitor (PI) has shown efficacy in treatment of newly diagnosed and relapsed AL amyloidosis, and is often used in combination with cyclophosphamide and dexamethasone. Ixazomib is the first oral PI to be approved in routine practice but has not been evaluated yet in the upf …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: Phase 2 trial of #Ninlaro/#Cytoxan/dex for untreated AL #amyloidosis finds hematologic response rate 63% (CR 11.4%, VGPR 37.1%), but 61% went to alternate Rx suggesting investigators don't have confidence in this regimen: https://t.co/EQ7azf5kX7. #mmsm https://t.co/ysK2xQ4Ec0
-
-
Mashup Score: 0The Stem Cell Transplant Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Muzaffar Qazilbash
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Stem Cell Transplant Daily! https://t.co/dITgyvLXVo Thanks to @Myeloma_Doc @PBeatingCancer #myeloma #ninlaro
-
-
Mashup Score: 1Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients - PubMed - 2 year(s) ago
The addition of ixazomib to lenalidomide maintenance demonstrated a better than expected PFS compared with historical data using lenalidomide alone and was safe and tolerable.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: @MDAndersonNews study of safety & efficacy of maintenance with #Ninlaro and #Revlimid in post-transplant #myeloma patients finds deepening response rates & median PFS of 73 months: https://t.co/growVh0OSx. https://t.co/QSKmaU1IlG
-
-
Mashup Score: 1
Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: UNITO-EMN10 trial data of #Ninlaro-based doublet and triplet induction regimens plus #Ninlaro maintenance in transplant-ineligible, newly diagnosed #myeloma finds none met target value of 2-year PFS of at least 65%: https://t.co/47KbWXC4ne. https://t.co/LrzjIMLHRx
-
-
Mashup Score: 3
Combination of IRD shows promising efficacy with manageable toxicity in patients with relapsed or refractory WM.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: Combining #Ninlaro with subcutaneous #Rituxan and dex in relapsed or refractory #Waldenström's macroglobulinemia gives overall response rate of 85% (50/59) & median duration of response of 36 months: https://t.co/1lYMBFRYBu. https://t.co/Ad8fkcd58g
-
-
Mashup Score: 0A randomized phase 3 study of ixazomib-dexamethasone versus physician's choice in relapsed or refractory AL amyloidosis - PubMed - 3 year(s) ago
In the first phase 3 study in relapsed/refractory AL amyloidosis (TOURMALINE-AL1 NCT01659658), 168 patients with relapsed/refractory AL amyloidosis after 1-2 prior lines were randomized to ixazomib (4 mg, days 1, 8, 15) plus dexamethasone (20 mg, days 1, 8, 15, 22; n = 85) or physician’s choice (dex …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: Randomized phase 3 study of #Ninlaro + dex versus physician's choice in relapsed or refractory AL #amyloidosis finds no difference in hematologic response rate but better median time to vital organ deterioration or mortality. https://t.co/5KJEkxX1VE . https://t.co/63o5l3ofGo
-
#Myeloma Paper of the Day: Phase 1/2 study of #Ninlaro/#Cytoxan/dex in newly diagnosed AL #amyloidosis finds 64% hematologic response rate (57% VGPR in median of 1.5 cycles), renal & cardiac responses in 50% and 22% of RP2D patients at 6 months: https://t.co/GRavvbBvs4. #mmsm https://t.co/LxVERJTPvR